Skip to main content

Table 2 Patient experiences and satisfaction with antifibrotic treatment after three and six months in the overall group (n = 75)

From: Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study

  Month 3 Month 6 Difference (95% CI) p-value
Satisfaction with effectiveness 1.6 (1.6) 1.6 (1.8) 0.0 (− 0.3–0.5) 0.70
Satisfaction with side-effects 1.8 (2.0) 1.6 (2.1) 0.2 (− 0.4–0.6) 0.57
Satisfaction with ease of use 2.9 (1.6) 2.7 (1.7) 0.2 (− 0.1–0.6) 0.18
Overall satisfaction with medication 2.1 (1.8) 2.1 (1.9) 0.0 (−0.4–0.5) 0.90
Experiences with effectiveness 2.0 (0.9) 2.0 (1.1) 0.0 (−0.4–0.5) 0.84
Experiences with side-effects 3.1 (1.1) 2.9 (1.2) 0.2 (−0.3–0.5) 0.44
Experiences with ease of use 3.9 (0.5) 3.8 (0.5) 0.1 (−0.1–0.2) 0.38
Number of reported side-effects per patient 6.4 (4.2) 5.8 (4.7) 0.6 (−0.2–1.4) 0.14
Severity score side-effects 9.5 (11.1) 8.7 (9.3) 0.8 (−1.6–3.2) 0.51
  1. Data are presented as mean (SD). Experiences are scored on a scale from 0 to 4; a higher score corresponds with more positive experiences. Satisfaction is scored on a scale from − 5 to 5